S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma

BACKGROUND: Gallbladder cancers and cholangiocarcinomas make up a heterogenous group of tumours with a poor prognosis in advanced stages. On the basis of evidence of dysregulation of the epidermal growth factor receptor, vascular endothelial growth factor and mitogen-activated protein kinase pathway...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Khoueiry, A B, Rankin, C, Siegel, A B, Iqbal, S, Gong, I-Y, Micetich, K C, Kayaleh, O R, Lenz, H-J, Blanke, C D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929880/
https://www.ncbi.nlm.nih.gov/pubmed/24423918
http://dx.doi.org/10.1038/bjc.2013.801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929880/
https://www.ncbi.nlm.nih.gov/pubmed/24423918
http://dx.doi.org/10.1038/bjc.2013.801

Ejemplares similares